The explosion of compounded GLP-1 choices over the previous two years is coming to an finish, and plenty of sufferers are left with no good choices.
Blockbuster weight problems and diabetes medicine — resembling Wegovy, Ozempic, and Mounjaro — are not deemed by regulators to be in scarcity, so compounding pharmacies and the telehealth corporations they work with should cease providing copies of the remedies.
Now, a whole lot of hundreds of sufferers are caught navigating uncharted waters as corporations they entrusted with their well being pursue methods which will disrupt their care or current dangers. Companies are altering prescriptions, mixing in components, or encouraging stockpiling of present compounded merchandise. Some have disappeared altogether.
That leaves many sufferers again at sq. one, struggling to afford the brand-name drugs, which carry record costs of about $1,000 a month. The pharma corporations promoting the branded medicine, Novo Nordisk and Eli Lilly, have began providing their remedies at decrease costs of round $350 to $700 a month, however that’s nonetheless unaffordable to many sufferers who have been getting compounded medicine at about $200 a month.
“That is type of like a lose-lose state of affairs,” stated Reshma Ramachandran, an assistant professor and well being providers researcher at Yale College who treats many sufferers who’ve turned to compounded GLP-1s as a result of they’ll’t afford the branded medicine.
Pharma corporations have been locked in authorized battles in opposition to compounders, arguing the copies that they make aren’t protected. (The FDA has obtained greater than 700 adversarial occasion experiences tied to compounded GLP-1s, but it surely’s not clear if the occasions have been brought on by the medicine.) The businesses additionally see compounders as a risk to their weight problems drug gross sales, that are estimated to balloon to $100 billion a yr by 2030. Lilly’s CEO Dave Ricks warned that the expansion of compounding may create a “backdoor generic world.”
This text is unique to STAT+ subscribers
Unlock this text — plus day by day protection and evaluation of the pharma business — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
